Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07082686

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Led by Beijing InnoCare Pharma Tech Co., Ltd. · Updated on 2026-04-27

75

Participants Needed

29

Research Sites

149 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.

CONDITIONS

Official Title

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years old or older
  • Histopathologically confirmed mantle cell lymphoma expressing Cyclin D1 and/or t (11;14) chromosomal translocation, with tissue samples provided for central pathology review
  • Diagnosed with relapsed or refractory mantle cell lymphoma
  • Previous treatment includes at least one adequate anti-CD20-containing therapy and one adequate BTK inhibitor-containing therapy
  • Failure of the last line of therapy
  • At least one measurable lesion according to the Lugano 2014 criteria
  • ECOG performance status of 0 to 2
Not Eligible

You will not qualify if you...

  • Blastoid or pleomorphic mantle cell lymphoma
  • Current or prior history of central nervous system lymphoma
  • Prior use of BCL-2 inhibitors such as venetoclax or ABT-199
  • Autologous stem cell transplantation or cellular therapy within 3 months before starting ICP-248
  • Prior allogeneic hematopoietic stem cell transplantation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 29 locations

1

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China, 230022

Actively Recruiting

2

Peking University Third Hospital

Beijing, Beijing Municipality, China, 100919

Actively Recruiting

3

West China Hospital of Sichuan University

Chengdu, Chengdu, China, 610041

Actively Recruiting

4

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China, 400016

Actively Recruiting

5

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China, 400030

Actively Recruiting

6

Fujian Medical University Union Hospital

Fuzhou, Fujian, China, 350001

Actively Recruiting

7

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China, 510050

Actively Recruiting

8

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510080

Actively Recruiting

9

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China, 530012

Actively Recruiting

10

Henan Cancer Hospital

Zhengzhou, Henan, China, 450000

Actively Recruiting

11

Henan Provincial People's Hospital

Zhengzhou, Henan, China, 450003

Actively Recruiting

12

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China, 451191

Actively Recruiting

13

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China, 430022

Actively Recruiting

14

Hunan Cancer Hospital

Changsha, Hunan, China, 410000

Actively Recruiting

15

The First Affiliated Hospital of University of South China

Hengyang, Hunan, China, 421001

Actively Recruiting

16

Jiangsu Province Hospital

Nanjing, Jiangsu, China, 210036

Actively Recruiting

17

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China, 330006

Actively Recruiting

18

The First Hospital of Jilin University

Changchun, Jilin, China, 130021

Actively Recruiting

19

Qilu Hospital of Shandong University

Jinan, Shandong, China, 250012

Actively Recruiting

20

Shandong Provincial Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, China, 250021

Actively Recruiting

21

Shandong Cancer Hospital

Jinan, Shandong, China, 250117

Actively Recruiting

22

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China, 266003

Actively Recruiting

23

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 200032

Actively Recruiting

24

The Second Affiliated Hospital of Xi'an Jiaotong University

Xian, Shanxi, China, 710004

Actively Recruiting

25

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China, 610072

Actively Recruiting

26

The Second People's Hospital of Yibin

Yibin, Sichuan, China, 644000

Actively Recruiting

27

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, China, 300020

Actively Recruiting

28

The Affiliated Cancer Hospital of Xinjiang Medical University

Xinjiang, Xinjiang, China, 830000

Actively Recruiting

29

The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

Loading map...

Research Team

A

Alexia Lu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) | DecenTrialz